Evidence map›Paper›PMID 28915557›Full record

ArticleOncotarget2017

Loss of p16

Ethika Tyagi, Bin Liu, Chelsea Li, Tong Liu, Jared Rutter, Douglas Grossman

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Senescent-Like Myofibers Contribute to Anti-Regenerative Cytokine Signaling in Duchenne Muscular Dystrophy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. p16Immunity & ageing : I & A · 2024
    Article
  7. Article
  8. Review
  9. P16INK4A-More Than a Senescence Marker.Life (Basel, Switzerland) · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. A novel CDKN2A variant (p16Pigment cell & melanoma research · 2019
    Article
  15. p16: cycling off the beaten path.Molecular & cellular oncology · 2019
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ethika Tyagi *The Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake, Utah, USA.
Bin Liu *The Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake, Utah, USA.
Chelsea LiThe Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake, Utah, USA.
Tong LiuThe Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake, Utah, USA.
Jared RutterThe Department of Biochemistry, University of Utah Health Sciences Center, Salt Lake, Utah, USA.
Douglas GrossmanThe Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake, Utah, USA.
Huntsman Cancer Institute · USUniversity of Utah · US

Funding

p16 mechanisms in melanomaR21CA201757 · NCI · UNIVERSITY OF UTAH · PI GROSSMAN, DOUGLAS · 2016 to 2017
$362k
NCI NIH HHS R21 CA201757
6 · The paper itself

Abstract

The tumor suppressor p16INK4A (p16) inhibits cell cycle progression through the CDK4/Rb pathway. We have previously shown that p16 regulates cellular oxidative stress, independent of its role in cell cycle control. We investigated whether loss of p16 had a direct impact on the mitochondria. We found that p16-null primary mouse fibroblasts (PMFs) displayed increased mitochondrial mass and expression of mitochondrial respiratory subunit proteins compared to wild-type (WT) PMFs. These findings in p16-null PMFs were associated with increased expression of the mitochondrial biogenesis transcription factors PRC and TFAM. On the other hand, p16-deficient PMFs demonstrated reduced mitochondrial respiration capacity consistent with electron microscopy findings showing that mitochondria in p16-deficient PMFs have abnormal morphology. Consistent with increased mitochondrial mass and reduced respiratory capacity, p16-deficient PMFs generated increased mitochondrial superoxide. One biological consequence of elevated ROS in p16-deficient PMFs was enhanced migration, which was reduced by the ROS scavenger N-acetylcysteine. Finally, p16-deficient PMFs displayed increased mitochondrial membrane potential, which was also required for their enhanced migration. The mitochondrial and migration phenotype was restored in p16-deficient PMFs by forced expression of p16. Similarly, over-expression of p16 in human melanocytes and A375 melanoma cells led to decreased expression of some mitochondrial respiratory proteins, enhanced respiration, and decreased migration. Inhibition of Rb phosphorylation in melanocytes and melanoma cells, either by addition of chemical CDK4 inhibitors or RNAi-mediated knockdown of CDK4, did not mimic the effects of p16 loss. These results suggest that p16 regulates mitochondrial biogenesis and function, which is independent of the canonical CDK4/Rb pathway.

Indexed as

CDK4fibroblastmigrationmitochondriap16

Identifiers

PMID28915557
PMCPMC5593528
OpenAlexW2744396185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.